Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer By Ogkologos - April 21, 2026 134 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Addressing Mental Health Needs of Adolescent and Young Adult Cancer Survivors March 11, 2021 College Basketball Star Plays First Game in Nearly Two Years After... December 1, 2020 Cuando necesita ayuda con responsabilidades de cuidado June 15, 2021 ‘Being open will help bring awareness’: Meet the fashion vlogger who... November 16, 2022 Load more HOT NEWS Enzalutamide Gets Added Approval for Prostate Cancer That Hasn’t Spread Thanks For Making This GivingTuesday Our Best One Yet! Neoadjuvant Camrelizumab Plus Chemotherapy Demonstrate Superior pCR Compared to Chemotherapy Alone... Young Adult Cancer Awareness Week: Recognizing Adolescent and Young Adults Cancer...
